Liquid Biopsy In Cancer Diagnostics Market To Witness Robust ~17% CAGR Expansion By 2032 Delveinsight

(MENAFN- GetNews)


"Liquid Biopsy in Cancer Diagnostics MarketLiquid Biopsy in Cancer Diagnostics Market"Liquid biopsy in cancer diagnostics companies such as Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc., MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., and several others.

Liquid Biopsy in Cancer Diagnostics Market Summary

The global Liquid Biopsy in Cancer Diagnostics Market is projected to grow steadily, driven by rising cancer incidence and demand for minimally invasive, precision medicine approaches. Key players include Myriad Genetics, Exact Sciences, Guardant Health, Illumina, QIAGEN, Thermo Fisher, and others. The market is segmented by product type (instruments, reagents, kits, services), sample type (blood, urine, saliva), biomarker type (CTCs, ctDNA, cfDNA), cancer type (lung, breast, colon, others), technique (PCR, NGS), end-user (hospitals, diagnostic centers), and geography. Valued at USD 7.64 billion in 2024, it is expected to reach USD 19.24 billion by 2032, growing at a CAGR of 16.64%.

DelveInsight's Liquid Biopsy in Cancer Diagnostics Market Insights report provides the current and forecast market analysis, individual leading liquid biopsy in cancer diagnostics companies' market shares, challenges, liquid biopsy in cancer diagnostics market drivers, barriers, trends, and key market liquid biopsy in cancer diagnostics companies in the market.

Unlock critical insights into the rapidly growing Liquid Biopsy in Cancer Diagnostics Market. Explore market trends, company shares, growth drivers, challenges, and future projections with DelveInsight's comprehensive report. Stay ahead in precision oncology and make informed strategic decisions today @ Liquid Biopsy in Cancer Diagnostics Market

Key Takeaways from the Liquid Biopsy in Cancer Diagnostics Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global liquid biopsy in cancer diagnostics market during the forecast period.
• Global liquid biopsy in cancer diagnostics market was valued at USD 7.64 billion in 2024, growing at a CAGR of 16.64% during the forecast period from 2025 to 2032 to reach USD 19.24 billion by 2032.
• Notable liquid biopsy in cancer diagnostics companies such as Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc., MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., and several others, are currently operating in the liquid biopsy in cancer diagnostics market.
• In April 2025, Labcorp announced the expansion of announced the expansion of its precision oncology portfolio with two new offerings. The first is Labcorp Plasma Detect, a clinical test designed to help evaluate the risk of disease recurrence in patients with stage III colon cancer. The second is PGDx elio plasma focus Dx, the first and only FDA-authorized kitted liquid biopsy test for pan-solid tumors, which supports the identification of patients who may be eligible for targeted therapies.
• In January 2025, Tempus AI, Inc. announced the launch of its FDA-approved next-generation sequencing (NGS)-based in vitro diagnostic test, xT CDx. The test is available to all ordering clinicians across the U.S. xT CDx provides comprehensive genomic insights through one of the largest FDA-approved gene panels currently on the market.

• In January 2025, Oxford Cancer Analytics (OXcan) announced that it raised $11 million in a Series a funding round, bringing the company's total funding raised to $16.7 million. The funding was raised to develop and commercialize novel minimally invasive liquid biopsy blood tests for the early detection of lung cancer.

• In January 2024, PrognomiQ, a healthcare firm dedicated to leveraging multi-omics data to revolutionize the early identification, treatment choice, and monitoring of cancer and intricate diseases, revealed encouraging findings from the most extensive deep multi-omics investigation to date. The study, available online in medRxiv, concentrated on individuals with susceptibility to lung cancer and showcased the effectiveness of multi-omics in achieving both heightened sensitivity and specificity for the early detection of lung cancer in its initial stages.
• In January 2024, Aditxt, Inc., a firm committed to exploring, advancing, and implementing promising healthcare breakthroughs, declares the successful acquisition of MDNA Life Sciences Inc.'s exclusive platform for early disease and cancer detection. This strategic decision further underscores Pearsanta, Inc.'s commitment to improving patient outcomes by focusing on early disease detection and the effectiveness of precision diagnostics.

To read more about the latest highlights related to liquid biopsy in cancer diagnostics market, get a snapshot of the key highlights entailed in the Global Liquid Biopsy in Cancer Diagnostics Market Report

Liquid Biopsy in Cancer Diagnostics Overview

Liquid biopsy is a revolutionary approach in cancer diagnostics that has emerged as a promising alternative to traditional tissue biopsies. Unlike conventional biopsies, which involve invasive procedures to extract tissue samples, liquid biopsy harnesses the power of a patient's blood or other bodily fluids to detect and analyze cancer-related genetic mutations, circulating tumor cells (CTCs), and cell-free DNA (cfDNA). This non-invasive technique offers a dynamic and real-time view of the tumor's genetic landscape, enabling oncologists to monitor disease progression, assess treatment response, and identify potential therapeutic targets with greater precision.

Liquid Biopsy in Cancer Diagnostics Market Insights

The Liquid Biopsy in Cancer Diagnostics Market is segmented by type (instruments, reagents & kits, services), sample type (blood, urine, saliva), biomarker (CTCs, ctDNA, cfDNA), cancer type (lung, breast, colon, others), technique (PCR, NGS), end-user (hospitals, diagnostic centers), and geography (North America, Europe, Asia-Pacific, Rest of the World).

In 2024, the services segment dominated with 73% of revenue due to comprehensive offerings from sample collection to NGS analysis, with companies like BARD1 and Biodesix leading. North America leads the market , driven by high cancer prevalence, strong oncology research, supportive government policies, insurance coverage, and favorable FDA programs. The US accounted for 87% of North American revenue , while risk factors such as aging and obesity further boost demand in countries like Mexico.

To know more about why North America is leading the market growth in the liquid biopsy in cancer diagnostics market, get a snapshot of the Liquid Biopsy in Cancer Diagnostics Market Outlook

Liquid Biopsy in Cancer Diagnostics Market Dynamics

The rising global cancer burden has increased the demand for alternatives to conventional biopsies, making liquid biopsy a crucial tool for smoother, less invasive cancer diagnosis. Liquid biopsies are increasingly applied in therapy management, particularly for lung and breast cancers, providing real-time tumor profiling to guide treatment decisions.

The growing adoption of precision medicine , which tailors treatments based on tumor biology, further drives liquid biopsy demand. Its non-invasive approach enables early detection, prognosis, therapy monitoring, and recurrence prediction. Market players are actively developing products, exemplified by collaborations like Molecular Health GmbH and EDGC for personalized cancer care.

However, challenges such as procedural limitations, risk of false results, and lack of standardization may constrain growth. Overall, liquid biopsy adoption is expected to expand significantly from 2025 to 2032.

Liquid Biopsy in Cancer Diagnostics Market Drivers:

• Rising Cancer Incidence: Increasing prevalence of cancers such as lung, breast, colorectal, and liver globally is driving demand for early detection and monitoring solutions.
• Minimally Invasive Testing: Liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, reducing patient discomfort and risk.
• Precision Medicine Adoption: Growing emphasis on individualized treatment plans requires real-time tumor profiling, which liquid biopsy facilitates.
• Technological Advancements: Innovations in next-generation sequencing (NGS) and PCR techniques improve sensitivity and accuracy of liquid biopsy tests.
• Regulatory Support and Insurance Coverage: Programs like FDA's Breakthrough Device designation and insurance reimbursement in countries such as the US encourage adoption.
• Clinical Applications: Broad applications in screening, diagnosis, and treatment monitoring, prognosis, and recurrence detection increase demand.

Liquid Biopsy in Cancer Diagnostics Market Barriers:

• Procedural Limitations: Technical challenges can lead to false positives or false negatives.
• Lack of Standardization: Variability in testing protocols across laboratories limits consistency and reliability.
• High Cost: Advanced liquid biopsy tests may be expensive, limiting accessibility in certain regions.
• Limited Awareness: Healthcare providers and patients may lack understanding of liquid biopsy benefits compared to conventional methods.

Get a sneak peek at the liquid biopsy in cancer diagnostics market dynamics @ Liquid Biopsy in Cancer Diagnostics Market Dynamics Analysis

Liquid Biopsy in Cancer Diagnostics Market Assessment

• Coverage: Global
• Study Period: 2022–2032
• Liquid Biopsy in Cancer Diagnostics Market CAGR: ~17%
• Liquid Biopsy in Cancer Diagnostics Market Size by 2032: USD 19.24 Billion
• Key Liquid Biopsy in Cancer Diagnostics Companies: Myriad Genetics Inc., Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., among others
• Liquid Biopsy in Cancer Diagnostics Market Segmentation By Type: Product Type [Instruments and Reagents & Kits] and Services), Sample Type (Blood, Urine, and Saliva), Biomarker Type (Circulating Tumor Cells, Circulating Tumor DNA, Circulating Free DNA, and Others), Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, and Others)
• Liquid Biopsy in Cancer Diagnostics Market Segmentation By Technique: Polymerase Chain Reaction and Next Generation Sequencing
• Liquid Biopsy in Cancer Diagnostics Market Segmentation By End User: Hospitals, Diagnostic Centers, and Others
• Liquid Biopsy in Cancer Diagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter's Five Forces Analysis, Product Profiles , Case Studies, KOL's Views, Analyst's View

Which MedTech key players in the liquid biopsy in cancer diagnostics market are set to emerge as the trendsetter explore @ Liquid Biopsy in Cancer Diagnostics Companies and Advancements

Table of Contents

1. Report Introduction

2. Executive summary

3. Regulatory and Patent Analysis

4. Key Factors Analysis

5. Porter's Five Forces Analysis

6. COVID-19 Impact Analysis on Liquid Biopsy in Cancer Diagnostics Market

7. Liquid Biopsy in Cancer Diagnostics Market Layout

8. Global Company Share Analysis – Key 3-5 Companies

9. Liquid Biopsy in Cancer Diagnostics Market Company and Product Profiles

10. Project Approach

11. About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

MENAFN03092025003238003268ID1110013831